
|Articles|October 8, 2020
QUIZ: The ALEX Study for ALK+ Non-Small Cell Lung Cancer
Author(s)Hannah Slater
In our lung cancer quiz, you’ll get to test your knowledge on the ALEX study.
Advertisement
What characteristics of alectinib therapy made it a viable treatment option versus crizotinib.
a. It has greater potency/selectivity for ALK.
b. It is a central nervous system penetrant.
c. It has the ability to target resistance mutations.
d. All of the above
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
2
Episode 16: Anticipated ESMO 2025 Data That May Change GU Oncology
3
Lenvatinib/Everolimus Beats Cabozantinib in Phase 2 RCC Study
4
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
5